{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:51:35Z","timestamp":1784069495227,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10157-023-02373-7","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T21:29:35Z","timestamp":1687555775000},"page":"819-827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Thirst intensity survey in ADPKD patients"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-5993","authenticated-orcid":false,"given":"Sibel Gokcay","family":"Gocay Bek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriye","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmud","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Ergul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irem","family":"Sar\u0131oglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Guven Taymez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Necmi","family":"Eren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hande","family":"Uslu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesude","family":"Tosun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"Dervisoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Kalender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Balc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Waldreus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"2373_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/S41572-018-0047-Y","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018. https:\/\/doi.org\/10.1038\/S41572-018-0047-Y.","journal-title":"Nat Rev Dis Primers"},{"key":"2373_CR2","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"2373_CR3","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930\u201372.","journal-title":"N Engl J Med"},{"key":"2373_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"RU M\u00fcller","year":"2022","unstructured":"M\u00fcller RU, Messchendorp AL, Birn H, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA working group on inherited kidney disorders, the European rare kidney disease reference network and polycystic kidney disease international. Nephrol Dial Transplant. 2022;37:825\u201339.","journal-title":"Nephrol Dial Transplant"},{"key":"2373_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/ndt\/gfy297","volume":"34","author":"VE Torres","year":"2019","unstructured":"Torres VE. Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2019;34:30\u20134.","journal-title":"Nephrol Dial Transplant"},{"key":"2373_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.06300615","volume":"11","author":"VE Torres","year":"2016","unstructured":"Torres VE, Higashihara E, Devuyst O, et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol. 2016;11:803\u201311.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2373_CR7","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2215\/CJN.01520218","volume":"13","author":"ME Edwards","year":"2018","unstructured":"Edwards ME, Chebib FT, Irazabal M, et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2018;13:1153\u201361.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2373_CR8","unstructured":"Physiology of thirst and drinking: implication for nursing practice-PubMed."},{"key":"2373_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ajkd.2017.08.020","volume":"71","author":"D Oberdhan","year":"2018","unstructured":"Oberdhan D, Cole JC, Krasa HB, et al. Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-life instrument. Am J Kidney Dis. 2018;71:225\u201335.","journal-title":"Am J Kidney Dis"},{"key":"2373_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000488233","volume":"72","author":"A Nutr","year":"2018","unstructured":"Nutr A, Bichet DG. Vasopressin and the regulation of thirst. Ann Nutr Metab. 2018;72:3\u20137.","journal-title":"Ann Nutr Metab"},{"key":"2373_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/1474515117728624","volume":"17","author":"N Waldr\u00e9us","year":"2018","unstructured":"Waldr\u00e9us N, Jaarsma T, van der Wal MHL, et al. Development and psychometric evaluation of the thirst distress scale for patients with heart failure. Eur J Cardiovasc Nurs. 2018;17:226\u201334.","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2373_CR12","unstructured":"WHODAS 2.0 Translation package whodas 2.0 translation package (version 1.0) translation and linguistic evaluation protocol and supporting material i. Preface."},{"key":"2373_CR13","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfu093","volume":"29","author":"E Higashihara","year":"2014","unstructured":"Higashihara E, Nutahara K, Tanbo M, et al. Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant. 2014;29:1710\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"2373_CR14","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s10157-016-1379-0","volume":"21","author":"M Katsumata","year":"2017","unstructured":"Katsumata M, Hirawa N, Sumida K, et al. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Clin Exp Nephrol. 2017;21:858\u201365.","journal-title":"Clin Exp Nephrol"},{"key":"2373_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ki.2011.119","volume":"80","author":"MV Irazabal","year":"2011","unstructured":"Irazabal MV, Torres VE, Hogan MC, et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2011;80:295\u2013301.","journal-title":"Kidney Int"},{"key":"2373_CR16","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1002\/ehf2.13395","volume":"8","author":"SH Eng","year":"2021","unstructured":"Eng SH, Waldr\u00e9us N, Gonz\u00e1lez B, et al. Thirst distress in outpatients with heart failure in a Mediterranean zone of Spain. ESC Heart Fail. 2021;8:2492.","journal-title":"ESC Heart Fail"},{"key":"2373_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1755-6686.2007.tb00069.x","volume":"33","author":"M Porcu","year":"2007","unstructured":"Porcu M, Fanton E, Zampieron A. Thirst distress and interdialytic weight gain: a study on a sample of haemodialysis patients. J Ren Care. 2007;33:179\u201381.","journal-title":"J Ren Care"},{"key":"2373_CR18","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s11255-016-1327-7","volume":"48","author":"B Kara","year":"2016","unstructured":"Kara B. Determinants of thirst distress in patients on hemodialysis. Int Urol Nephrol. 2016;48:1525\u201332.","journal-title":"Int Urol Nephrol"},{"key":"2373_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1159\/000355717","volume":"37","author":"J-Y Niu","year":"2013","unstructured":"Niu J-Y, Fan W-F, Zhang Q, et al. Study on the clinical significance and related factors of thirst and xerostomia in maintenance hemodialysis patients. Kidney Blood Press Res. 2013;37:464\u201374.","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"2373_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-771X.2012.01143.x","volume":"6","author":"\u0130 Altun","year":"2012","unstructured":"Altun \u0130, \u00c7\u0131nar ND, Ka\u015f\u0131k\u00e7\u0131 MK. Self-reported quantity of daily water intake and urine output in healthy young. Int J Urol Nurs. 2012;6(2):91\u20133. https:\/\/doi.org\/10.1111\/j.1749-771X.2012.01143.x.","journal-title":"Int J Urol Nurs"},{"key":"2373_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4103\/jpcs.jpcs_8_21","volume":"7","author":"K Thapa","year":"2021","unstructured":"Thapa K, Das S, Pathak P, et al. Assessment of thirst intensity and thirst distress and the practices for its management among heart failure patients admitted to the cardiology unit. J Pract Cardiovas Sci. 2021;7:36.","journal-title":"J Pract Cardiovas Sci"},{"key":"2373_CR22","first-page":"2223","volume":"12","author":"N Waldr\u00e9us","year":"2018","unstructured":"Waldr\u00e9us N, Chung ML, van der Wal MHL, et al. Trajectory of thirst intensity and distress from admission to 4-weeks follow up at home in patients with heart failure. Pat Prefer Adher. 2018;12:2223\u201331.","journal-title":"Pat Prefer Adher"},{"key":"2373_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/S13741-017-0081-4","author":"F Hughes","year":"2018","unstructured":"Hughes F, Mythen M, Montgomery H. The sensitivity of the human thirst response to changes in plasma osmolality: a systematic review. Periop Med. 2018. https:\/\/doi.org\/10.1186\/S13741-017-0081-4.","journal-title":"Periop Med"},{"key":"2373_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDOA2100021","author":"GK Rangan","year":"2021","unstructured":"Rangan GK, Wong ATY, Munt A, et al. Prescribed water intake in autosomal dominant polycystic kidney disease. NEJM Evidence. 2021. https:\/\/doi.org\/10.1056\/EVIDOA2100021.","journal-title":"NEJM Evidence"},{"key":"2373_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.semnephrol.2008.03.003","volume":"28","author":"VE Torres","year":"2008","unstructured":"Torres VE. Vasopressin antagonists in polycystic kidney disease. Semin Nephrol. 2008;28:306.","journal-title":"Semin Nephrol"},{"key":"2373_CR26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ki.1989.38","volume":"35","author":"PA Gabow","year":"1989","unstructured":"Gabow PA, Kaehny WD, Johnson AM, et al. The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int. 1989;35:675\u201380.","journal-title":"Kidney Int"},{"key":"2373_CR27","doi-asserted-by":"publisher","first-page":"17666","DOI":"10.1038\/s41598-021-97113-w","volume":"11","author":"K Uchiyama","year":"2021","unstructured":"Uchiyama K, Kitayama C, Yanai A, et al. The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial. Sci Rep. 2021;11:17666.","journal-title":"Sci Rep"},{"key":"2373_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-018-0957-7","volume":"19","author":"BJ Kramers","year":"2018","unstructured":"Kramers BJ, van Gastel MDA, Meijer E, et al. Case report: a thiazide diuretic to treat polyuria induced by tolvaptan. BMC Nephrol. 2018;19:1\u20135.","journal-title":"BMC Nephrol"},{"key":"2373_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000463063","volume":"70","author":"MDA van Gastel","year":"2017","unstructured":"van Gastel MDA, Torres VE. Polycystic kidney disease and the vasopressin pathway. Ann Nutr Metab. 2017;70:43\u201350.","journal-title":"Ann Nutr Metab"}],"updated-by":[{"DOI":"10.1007\/s10157-023-02375-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000}}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-023-02373-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:12:56Z","timestamp":1694751176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-023-02373-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2373"],"URL":"https:\/\/doi.org\/10.1007\/s10157-023-02373-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10157-023-02375-5","asserted-by":"object"}]},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"assertion":[{"value":"5 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10157-023-02375-5","URL":"https:\/\/doi.org\/10.1007\/s10157-023-02375-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study complies with the Declaration of Helsinki. Ethics approval for the study was obtained from the Ethics Committee of Kocaeli University Hospital (GOKAEK-2021\/12.03). Written informed consent was obtained from the participants who volunteered to take the survey and participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}